You just read:

Biomarker Analyses of Neuraltus Pharmaceuticals' NP001 Phase 2 Data Demonstrate Potential for Treating ALS Patients with Systemic Inflammation

News provided by

Neuraltus Pharmaceuticals, Inc.

Apr 04, 2016, 08:30 ET